cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.25402/bmm.21828417
title: Supplementary Table 3 - LRP1B as a potential gastric cancer biomarker

description: <strong>Background: </strong>The aim of this study was to discover unique membrane proteins associated with gastric cancer (GC) in proteomics analysis. <strong>Methods: </strong>Using a data-independent acquisition strategy, we compared the relative expression levels of membrane proteins in GC. <strong>Results: </strong>A total of 2774 differentially expressed membrane proteins were identified between GC and normal cell lines. Conjoint analysis of transcriptomes and proteomes provided 11 potential biomarkers (GPRC5A, PSAT1, NUDCD1, RCC2, IPO4, FAM91A1, KANK2, PRADC1, NME4, METTL7A and LRP1B) for further exploration. Downregulation of LRP1B in GC was validated by immunohistochemistry. Moreover, LRP1B demonstrated an area under the receiver operating characteristic curve of 0.917 in differentiating GC from normal tissues. <strong>Conclusion: </strong>LRP1B was identified as a meaningful indicator assisting in GC detection and labeling of tumor boundaries.
DOI: 10.25402/bmm.21828417.v1
title: Supplementary Table 3 - LRP1B as a potential gastric cancer biomarker

description: <strong>Background: </strong>The aim of this study was to discover unique membrane proteins associated with gastric cancer (GC) in proteomics analysis. <strong>Methods: </strong>Using a data-independent acquisition strategy, we compared the relative expression levels of membrane proteins in GC. <strong>Results: </strong>A total of 2774 differentially expressed membrane proteins were identified between GC and normal cell lines. Conjoint analysis of transcriptomes and proteomes provided 11 potential biomarkers (GPRC5A, PSAT1, NUDCD1, RCC2, IPO4, FAM91A1, KANK2, PRADC1, NME4, METTL7A and LRP1B) for further exploration. Downregulation of LRP1B in GC was validated by immunohistochemistry. Moreover, LRP1B demonstrated an area under the receiver operating characteristic curve of 0.917 in differentiating GC from normal tissues. <strong>Conclusion: </strong>LRP1B was identified as a meaningful indicator assisting in GC detection and labeling of tumor boundaries.
DOI: 10.25402/bmm.21878496
title: Supplemental Table 3 v 10-28-22.docxGender differences contribute to variability of serum lipid biomarkers for Alzheimer’s disease -

description: Background: Alzheimer’s disease (AD) cannot currently be diagnosed by a blood test. One reason may be gender differences. Another may be the statistical methods used. The authors evaluate these possibilities. Objective: The authors applied serum lipidomics to find AD biomarkers in men and women. They hypothesized that AD biomarkers would differ between genders and that machine-learning algorithms would improve diagnostic performance. Methods: Serum lipids were analyzed by mass spectrometry for a training set of AD cases and controls and in a blinded test set. Statistical analyses considered gender differences. Results: Lipids best classifying AD subjects differed significantly between men and women. Robust statistical algorithms did not improve diagnostic performance. Conclusion: Poor performance of AD biomarkers appears to be due primarily to inherent variability in AD patients.
<br>
Plain language summary: Alzheimer’s disease (AD) cannot be diagnosed by a blood test or radiologic study. Newer laboratorymethods usingmass spectrometers have successfully identified molecules in blood that mark the presence of other diseases, but such approaches have failed to find diagnostic biomarkers for AD. Often, initial studies of serum from AD cases and controls have provided promising diagnostic biomarkers, but follow-up studies have not confirmed their usefulness. This study attempts to clarify why this is so by carrying out a serum lipid (fatty molecule) analysis using mass spectrometry (MS) in both an initial serum set of AD cases and matched controls and applying those results to AD diagnosis in a second, independent set of specimens. Sources of variability that could prevent the discovery of useful markers using MS analyses of serum include specimen integrity, variable MS results, problems with statistical methods that analyze MS data and inherent AD patient variability reflected in their sera.
DOI: 10.25402/bmm.21878502
title: Gender differences contribute to variability of serum lipid biomarkers for Alzheimer’s disease - Supplemental Table 1

description: Background: Alzheimer’s disease (AD) cannot currently be diagnosed by a blood test. One reason may be gender differences. Another may be the statistical methods used. The authors evaluate these possibilities. Objective: The authors applied serum lipidomics to find AD biomarkers in men and women. They hypothesized that AD biomarkers would differ between genders and that machine-learning algorithms would improve diagnostic performance. Methods: Serum lipids were analyzed by mass spectrometry for a training set of AD cases and controls and in a blinded test set. Statistical analyses considered gender differences. Results: Lipids best classifying AD subjects differed significantly between men and women. Robust statistical algorithms did not improve diagnostic performance. Conclusion: Poor performance of AD biomarkers appears to be due primarily to inherent variability in AD patients.
<br>
Plain language summary: Alzheimer’s disease (AD) cannot be diagnosed by a blood test or radiologic study. Newer laboratorymethods usingmass spectrometers have successfully identified molecules in blood that mark the presence of other diseases, but such approaches have failed to find diagnostic biomarkers for AD. Often, initial studies of serum from AD cases and controls have provided promising diagnostic biomarkers, but follow-up studies have not confirmed their usefulness. This study attempts to clarify why this is so by carrying out a serum lipid (fatty molecule) analysis using mass spectrometry (MS) in both an initial serum set of AD cases and matched controls and applying those results to AD diagnosis in a second, independent set of specimens. Sources of variability that could prevent the discovery of useful markers using MS analyses of serum include specimen integrity, variable MS results, problems with statistical methods that analyze MS data and inherent AD patient variability reflected in their sera.
DOI: 10.25402/bmm.21878505
title: Gender differences contribute to variability of serum lipid biomarkers for Alzheimer’s disease - Supplemental Table 2

description: Background: Alzheimer’s disease (AD) cannot currently be diagnosed by a blood test. One reason may be gender differences. Another may be the statistical methods used. The authors evaluate these possibilities. Objective: The authors applied serum lipidomics to find AD biomarkers in men and women. They hypothesized that AD biomarkers would differ between genders and that machine-learning algorithms would improve diagnostic performance. Methods: Serum lipids were analyzed by mass spectrometry for a training set of AD cases and controls and in a blinded test set. Statistical analyses considered gender differences. Results: Lipids best classifying AD subjects differed significantly between men and women. Robust statistical algorithms did not improve diagnostic performance. Conclusion: Poor performance of AD biomarkers appears to be due primarily to inherent variability in AD patients.
<br>
Plain language summary: Alzheimer’s disease (AD) cannot be diagnosed by a blood test or radiologic study. Newer laboratorymethods usingmass spectrometers have successfully identified molecules in blood that mark the presence of other diseases, but such approaches have failed to find diagnostic biomarkers for AD. Often, initial studies of serum from AD cases and controls have provided promising diagnostic biomarkers, but follow-up studies have not confirmed their usefulness. This study attempts to clarify why this is so by carrying out a serum lipid (fatty molecule) analysis using mass spectrometry (MS) in both an initial serum set of AD cases and matched controls and applying those results to AD diagnosis in a second, independent set of specimens. Sources of variability that could prevent the discovery of useful markers using MS analyses of serum include specimen integrity, variable MS results, problems with statistical methods that analyze MS data and inherent AD patient variability reflected in their sera.
DOI: 10.25402/bmm.21878508
title: Gender differences contribute to variability of serum lipid biomarkers for Alzheimer’s disease - Supplemental Table 4

description: Background: Alzheimer’s disease (AD) cannot currently be diagnosed by a blood test. One reason may be gender differences. Another may be the statistical methods used. The authors evaluate these possibilities. Objective: The authors applied serum lipidomics to find AD biomarkers in men and women. They hypothesized that AD biomarkers would differ between genders and that machine-learning algorithms would improve diagnostic performance. Methods: Serum lipids were analyzed by mass spectrometry for a training set of AD cases and controls and in a blinded test set. Statistical analyses considered gender differences. Results: Lipids best classifying AD subjects differed significantly between men and women. Robust statistical algorithms did not improve diagnostic performance. Conclusion: Poor performance of AD biomarkers appears to be due primarily to inherent variability in AD patients.
<br>
Plain language summary: Alzheimer’s disease (AD) cannot be diagnosed by a blood test or radiologic study. Newer laboratorymethods usingmass spectrometers have successfully identified molecules in blood that mark the presence of other diseases, but such approaches have failed to find diagnostic biomarkers for AD. Often, initial studies of serum from AD cases and controls have provided promising diagnostic biomarkers, but follow-up studies have not confirmed their usefulness. This study attempts to clarify why this is so by carrying out a serum lipid (fatty molecule) analysis using mass spectrometry (MS) in both an initial serum set of AD cases and matched controls and applying those results to AD diagnosis in a second, independent set of specimens. Sources of variability that could prevent the discovery of useful markers using MS analyses of serum include specimen integrity, variable MS results, problems with statistical methods that analyze MS data and inherent AD patient variability reflected in their sera.
DOI: 10.25402/bmm.21932070
title: Linkage of calprotectin with inflammation, activity and treatment response of rheumatoid arthritis: a meta-analysis Supplementary table 1

description: Aim: This meta-analysis aimed to investigate the clinical value of calprotectin in rheumatoid arthritis (RA) patients. Methods: The data regarding blood calprotectin levels in RA patients were retrieved from PubMed, Embase, Web of Science and Cochrane databases. Results: Thirty-one eligible articles were included. Calprotectin was increased in RA patients compared with healthy controls (mean difference [MD] = 1.48, 95% CI: 1.16–1.79). Calprotectin was positively associated with C-reactive protein (correlation coefficient [CC] = 0.58, 95% CI: 0.53–0.63) and disease activity score (CC = 0.48, 95% CI: 0.38–0.58) in RA patients. Interestingly, calprotectin showed an increased trend in RA responders compared with nonresponders, but without statistical significance (MD = 0.38, 95% CI: -0.09–0.85). Conclusion: Blood calprotectin relates to disease risk, inflammation and activity in RA patients.
DOI: 10.25402/bmm.21932070.v1
title: Linkage of calprotectin with inflammation, activity and treatment response of rheumatoid arthritis: a meta-analysis Supplementary table 1

description: Aim: This meta-analysis aimed to investigate the clinical value of calprotectin in rheumatoid arthritis (RA) patients. Methods: The data regarding blood calprotectin levels in RA patients were retrieved from PubMed, Embase, Web of Science and Cochrane databases. Results: Thirty-one eligible articles were included. Calprotectin was increased in RA patients compared with healthy controls (mean difference [MD] = 1.48, 95% CI: 1.16–1.79). Calprotectin was positively associated with C-reactive protein (correlation coefficient [CC] = 0.58, 95% CI: 0.53–0.63) and disease activity score (CC = 0.48, 95% CI: 0.38–0.58) in RA patients. Interestingly, calprotectin showed an increased trend in RA responders compared with nonresponders, but without statistical significance (MD = 0.38, 95% CI: -0.09–0.85). Conclusion: Blood calprotectin relates to disease risk, inflammation and activity in RA patients.
DOI: 10.25402/bmm.21932073
title: Linkage of calprotectin with inflammation, activity and treatment response of rheumatoid arthritis: a meta-analysis Supplementary table 2 - PRISMA Checklist

description: Aim: This meta-analysis aimed to investigate the clinical value of calprotectin in rheumatoid arthritis (RA) patients. Methods: The data regarding blood calprotectin levels in RA patients were retrieved from PubMed, Embase, Web of Science and Cochrane databases. Results: Thirty-one eligible articles were included. Calprotectin was increased in RA patients compared with healthy controls (mean difference [MD] = 1.48, 95% CI: 1.16–1.79). Calprotectin was positively associated with C-reactive protein (correlation coefficient [CC] = 0.58, 95% CI: 0.53–0.63) and disease activity score (CC = 0.48, 95% CI: 0.38–0.58) in RA patients. Interestingly, calprotectin showed an increased trend in RA responders compared with nonresponders, but without statistical significance (MD = 0.38, 95% CI: -0.09–0.85). Conclusion: Blood calprotectin relates to disease risk, inflammation and activity in RA patients.
DOI: 10.25402/bmm.21932073.v1
title: Linkage of calprotectin with inflammation, activity and treatment response of rheumatoid arthritis: a meta-analysis Supplementary table 2 - PRISMA Checklist

description: Aim: This meta-analysis aimed to investigate the clinical value of calprotectin in rheumatoid arthritis (RA) patients. Methods: The data regarding blood calprotectin levels in RA patients were retrieved from PubMed, Embase, Web of Science and Cochrane databases. Results: Thirty-one eligible articles were included. Calprotectin was increased in RA patients compared with healthy controls (mean difference [MD] = 1.48, 95% CI: 1.16–1.79). Calprotectin was positively associated with C-reactive protein (correlation coefficient [CC] = 0.58, 95% CI: 0.53–0.63) and disease activity score (CC = 0.48, 95% CI: 0.38–0.58) in RA patients. Interestingly, calprotectin showed an increased trend in RA responders compared with nonresponders, but without statistical significance (MD = 0.38, 95% CI: -0.09–0.85). Conclusion: Blood calprotectin relates to disease risk, inflammation and activity in RA patients.
DOI: 10.25402/bmm.22100906
title: GDF-15 and soluble ST2 as biomarkers ofright ventricular dysfunction in pulmonaryhypertension Supplementary Table 1

description: Background: This study analyzed the utility of soluble ST2 (sST2) and GDF-15 as biomarkers of right ventricular (RV) function in patients with pulmonary hypertension (PH). Methods: GDF-15 and sST2 serum concentrations were measured in patients with PH (n = 628), dilated cardiomyopathy (n = 31) and left ventricular hypertrophy (n = 47), and in healthy controls (n = 61). Results: Median sST2 and GDF-15 levels in patients with left ventricular hypertrophy were higher than in patients with PH and dilated cardiomyopathy. In tertile analysis GDF-15 &gt;1363 pg/ml and sST2 &gt;38 ng/ml were associated with higher N-terminal pro-brain natriuretic peptide, RV systolic dysfunction, RV-pulmonary arterial uncoupling and hemodynamic impairment. Conclusion: GDF-15 and sST2 are potential biomarkers of RV dysfunction in patients with PH.
DOI: 10.25402/bmm.22100906.v1
title: GDF-15 and soluble ST2 as biomarkers ofright ventricular dysfunction in pulmonaryhypertension Supplementary Table 1

description: Background: This study analyzed the utility of soluble ST2 (sST2) and GDF-15 as biomarkers of right ventricular (RV) function in patients with pulmonary hypertension (PH). Methods: GDF-15 and sST2 serum concentrations were measured in patients with PH (n = 628), dilated cardiomyopathy (n = 31) and left ventricular hypertrophy (n = 47), and in healthy controls (n = 61). Results: Median sST2 and GDF-15 levels in patients with left ventricular hypertrophy were higher than in patients with PH and dilated cardiomyopathy. In tertile analysis GDF-15 &gt;1363 pg/ml and sST2 &gt;38 ng/ml were associated with higher N-terminal pro-brain natriuretic peptide, RV systolic dysfunction, RV-pulmonary arterial uncoupling and hemodynamic impairment. Conclusion: GDF-15 and sST2 are potential biomarkers of RV dysfunction in patients with PH.
DOI: 10.15468/dl.neewug
title: Occurrence Download

description: A dataset containing 47 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is BOLD:AAW3746"
 ]
}

 The dataset includes 47 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0019494-240506114902167/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.25402/bmm.22100915
title: GDF-15 and soluble ST2 as biomarkers of right ventricular dysfunction in pulmonaryhypertension Supplementary Table 2

description: Background: This study analyzed the utility of soluble ST2 (sST2) and GDF-15 as biomarkers of right ventricular (RV) function in patients with pulmonary hypertension (PH). Methods: GDF-15 and sST2 serum concentrations were measured in patients with PH (n = 628), dilated cardiomyopathy (n = 31) and left ventricular hypertrophy (n = 47), and in healthy controls (n = 61). Results: Median sST2 and GDF-15 levels in patients with left ventricular hypertrophy were higher than in patients with PH and dilated cardiomyopathy. In tertile analysis GDF-15 &gt;1363 pg/ml and sST2 &gt;38 ng/ml were associated with higher N-terminal pro-brain natriuretic peptide, RV systolic dysfunction, RV-pulmonary arterial uncoupling and hemodynamic impairment. Conclusion: GDF-15 and sST2 are potential biomarkers of RV dysfunction in patients with PH.
DOI: 10.25402/nnm.14595966.v1
title: Supplementary Tables: Nanoscale pathogens treated with nanomaterial-like peptides: a platform technology appropriate for future pandemics.docx

description: <b>Supplementary
 Tables</b>
DOI: 10.25402/bmm.22100915.v1
title: GDF-15 and soluble ST2 as biomarkers of right ventricular dysfunction in pulmonaryhypertension Supplementary Table 2

description: Background: This study analyzed the utility of soluble ST2 (sST2) and GDF-15 as biomarkers of right ventricular (RV) function in patients with pulmonary hypertension (PH). Methods: GDF-15 and sST2 serum concentrations were measured in patients with PH (n = 628), dilated cardiomyopathy (n = 31) and left ventricular hypertrophy (n = 47), and in healthy controls (n = 61). Results: Median sST2 and GDF-15 levels in patients with left ventricular hypertrophy were higher than in patients with PH and dilated cardiomyopathy. In tertile analysis GDF-15 &gt;1363 pg/ml and sST2 &gt;38 ng/ml were associated with higher N-terminal pro-brain natriuretic peptide, RV systolic dysfunction, RV-pulmonary arterial uncoupling and hemodynamic impairment. Conclusion: GDF-15 and sST2 are potential biomarkers of RV dysfunction in patients with PH.
DOI: 10.25402/bmm.22134137
title: IL6R gene polymorphisms and their relation to chronic obstructive pulmonary disease susceptibility in the Chinese population Supplementary Tables 1-5

description: Background: This work was designed to explore the correlation between IL6R polymorphisms and chronic
obstructive pulmonary disease (COPD) susceptibility. Methods: Agena MassARRAY was used to genotype
five SNPs of IL6R in 498 patients with COPD and 498 controls. Genetic models and haplotype analysis
were used to assess the associations between SNPs and COPD risk. Results: Rs6689306 and rs4845625
increase the risk of COPD. Rs4537545, rs4129267 and rs2228145 were related to a decreased risk of COPD in
different subgroups. Haplotype analysis revealed that GTCTC, GCCCA and GCTCA contributed to a reduced
risk of COPD after adjustment. Conclusion: IL6R polymorphisms are significantly associated with COPD
susceptibility.
DOI: 10.25402/bmm.22134137.v1
title: IL6R gene polymorphisms and their relation to chronic obstructive pulmonary disease susceptibility in the Chinese population Supplementary Tables 1-5

description: Background: This work was designed to explore the correlation between IL6R polymorphisms and chronic
obstructive pulmonary disease (COPD) susceptibility. Methods: Agena MassARRAY was used to genotype
five SNPs of IL6R in 498 patients with COPD and 498 controls. Genetic models and haplotype analysis
were used to assess the associations between SNPs and COPD risk. Results: Rs6689306 and rs4845625
increase the risk of COPD. Rs4537545, rs4129267 and rs2228145 were related to a decreased risk of COPD in
different subgroups. Haplotype analysis revealed that GTCTC, GCCCA and GCTCA contributed to a reduced
risk of COPD after adjustment. Conclusion: IL6R polymorphisms are significantly associated with COPD
susceptibility.
DOI: 10.25402/nnm.14625957.v1
title: Supplementary Table 1. Silver nanoparticles induce apoptosis via NOX4-derived mitochondrial ROS and ER stress in colorectal cancer cells

description: <b>Supplementary Table 1. </b>The sequence details of NOX family
 and ER stress related gene primer used in PCR.
DOI: 10.25402/bmm.22786418
title: Serum HMGB1 and soluble urokinase plasminogen activator receptor levels aid diagnosis and prognosis prediction of sepsis with acute respiratory distress syndrome - Supplementary table

description: Objective: To study the clinical application of serum HMGB1 and soluble urokinase plasminogen activator
receptor (suPAR) expression in sepsis with acute respiratory distress syndrome (ARDS). Methods: Clinical
data of 303 septic patients with/without ARDS were documented. Levels of serum inflammatory markers
and HMGB1/suPAR were measured. ARDS patients were subdivided into high and low HMGB1/suPAR
expression groups and followed up. Results: Serum HMGB1 and suPAR were upregulated in ARDS patients
and positively correlated with inflammatory markers. The combination of HMGB1 with suPAR surpassed
HMGB1 or suPAR alone in aiding diagnosis of sepsis with ARDS. CRP, PCT, IL-6, HMGB1 and suPAR were
independent risk factors for ARDS. High HMGB1/suPAR expression might be linked to poor prognosis.
Conclusion: Serum HMGB1/suPAR levels might aid diagnosis and predict poor prognosis of septic patients
with ARDS.
DOI: 10.25402/bmm.22786418.v1
title: Serum HMGB1 and soluble urokinase plasminogen activator receptor levels aid diagnosis and prognosis prediction of sepsis with acute respiratory distress syndrome - Supplementary table

description: Objective: To study the clinical application of serum HMGB1 and soluble urokinase plasminogen activator
receptor (suPAR) expression in sepsis with acute respiratory distress syndrome (ARDS). Methods: Clinical
data of 303 septic patients with/without ARDS were documented. Levels of serum inflammatory markers
and HMGB1/suPAR were measured. ARDS patients were subdivided into high and low HMGB1/suPAR
expression groups and followed up. Results: Serum HMGB1 and suPAR were upregulated in ARDS patients
and positively correlated with inflammatory markers. The combination of HMGB1 with suPAR surpassed
HMGB1 or suPAR alone in aiding diagnosis of sepsis with ARDS. CRP, PCT, IL-6, HMGB1 and suPAR were
independent risk factors for ARDS. High HMGB1/suPAR expression might be linked to poor prognosis.
Conclusion: Serum HMGB1/suPAR levels might aid diagnosis and predict poor prognosis of septic patients
with ARDS.